| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/INFDIS/162.3.735 |
| P698 | PubMed publication ID | 2387997 |
| P2093 | author name string | Wainberg MA | |
| Tremblay M | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 735-737 | |
| P577 | publication date | 1990-09-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera | |
| P478 | volume | 162 |
| Q45723228 | A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1. |
| Q40569839 | Antigenic variation of primate lentiviruses in humans and experimentally infected macaques |
| Q35956940 | Association of enhanced HIV-1 neutralization by a single Y681H substitution in gp41 with increased gp120-CD4 interaction and macrophage infectivity |
| Q39577849 | Autologous and heterologous neutralization analyses of primary feline immunodeficiency virus isolates |
| Q36635390 | Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization |
| Q35880498 | Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1 |
| Q35548590 | Diversity and variation in human immunodeficiency virus: implications for immune control |
| Q36634778 | Effects of natural sequence variation on recognition by monoclonal antibodies neutralize simian immunodeficiency virus infectivity. |
| Q40393218 | Envelope Sequence Variation, Neutralizing Antibodies, and Primate Lentivirus Persistence |
| Q45406304 | Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro. |
| Q34819651 | Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic |
| Q36633502 | Extensive envelope heterogeneity of simian immunodeficiency virus in tissues from infected macaques |
| Q45777616 | Extensive sequence variation of feline immunodeficiency virus env genes in isolates from naturally infected cats |
| Q40760950 | Fine characterization of a V3-region neutralizing epitope in human immunodeficiency virus type 2. |
| Q36650881 | Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions |
| Q40631515 | HIV-1 antibodies and serology. |
| Q71992801 | HIV-1 infection of in vitro cultured human monocytes: early events and influence of anti HIV-1 antibodies |
| Q45859822 | Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus |
| Q28602877 | Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies |
| Q35892184 | Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off. |
| Q33504604 | Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection |
| Q37410770 | Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment |
| Q35866030 | Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody |
| Q36654750 | Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. |
| Q34647680 | Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy |
| Q33860721 | Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. |
| Q34419527 | Neutralizing antiviral antibody responses |
| Q35034062 | On natural and artificial vaccinations |
| Q35665921 | Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1 |
| Q35022653 | Public versus personal serotypes of a viral quasispecies. |
| Q33640144 | R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models |
| Q29618603 | Rapid evolution of the neutralizing antibody response to HIV type 1 infection |
| Q41657049 | Recombinant gpl35 envelope glycoproteins of caprine arthritis-encephalitis lentivirus variants inhibit homologous and heterologous variant-specific neutralizing antibodies |
| Q35841780 | Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. |
| Q39594428 | Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. |
| Q41597581 | Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network |
| Q36650125 | Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys |
| Q34415389 | Specificity of the autologous neutralizing antibody response |
| Q37590197 | Surveillance programs for detection and characterization of emergent pathogens and antimicrobial resistance: results from the Division of Infectious Diseases, UNIFESP. |
| Q40906322 | Two PBMC-based neutralization assays depict low reactivity of both anti-V3 monoclonal antibodies and immune sera against HIV-1 primary isolates |
| Q36636293 | Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge |
Search more.